Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Duchenne muscular dystrophy drug, deramiocel, to November 22. This extension, due to a major amendment submitted by Capricor, is being viewed positively by investors as it avoids a Complete Response Letter and keeps approval hopes alive, despite a previous negative advisory panel vote.
The FDA extended the PDUFA target action date for Capricor Therapeutics' deramiocel, a Duchenne muscular dystrophy treatment, to November 22. This extension is a result of Capricor submitting a major amendment to its marketing application, including new 24-month open-label extension data and robustness analyses. Investors are reacting positively because the FDA did not issue a Complete Response Letter, which would have required additional studies and significantly delayed the drug. This keeps the possibility of approval alive, despite a prior negative advisory committee vote. Short-term, this provides a boost to CAPR stock, but long-term approval is still uncertain given the FDA's previous concerns. The key opportunity for traders is the continued hope for approval, while the risk remains the ultimate FDA decision in November.